Skip to main content
Figure 4 | BMC Musculoskeletal Disorders

Figure 4

From: Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]

Figure 4

Primary endpoints evaluating efficacy of etoricoxib. LS Mean Change from Baseline is shown for patients receiving 30, 60 or 90 mg etoricoxib for up to 52 weeks. Modified Intention-to-Treat Approach With Last Value Carried Forward was performed. As the numbers of patients were small and decreased over time, data should be interpreted with caution. Screening (S) to baseline (R) = NSAID washout period; SE = Standard error â—‹ = 30 mg etoricoxib; * = 60 mg etoricoxib; â—† = 90 mg etoricoxib.

Back to article page